Compare Campbell Soup Co. (CPB) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Pfizer Inc — how do they compare? Campbell Soup Co. trades at $22.79 (market cap $6.69B), while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 23× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.96%). Which is the better fit depends on your goals.
| CPB | PFE | |
|---|---|---|
Market Cap | $6.69B | $154.18B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $28.56 |
52-Week Low | $20.00 | $23.60 |
Enterprise Value | $13.29B | $205.67B |
Dividend Yield | 6.96% | 6.36% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $23.05, up 2.17% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings beat expectations in Q1 2026, while analyst sentiment remains cautious with only 3.45% buy ratings. The stock offers a 6.8% dividend yield, supported by positive cash flow from operations of $1.13B in 2025.
The outlook remains mixed with cost-saving initiatives and product innovation providing upside potential, but persistent margin challenges and high debt levels pose significant risks. Current valuation appears reasonable with P/E of 11.29, though weak analyst consensus suggests limited near-term catalyst for price appreciation beyond dividend income.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
